Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02649218 · ClinicalTrials.gov registry record · Phase 2
A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 226
- Enrollment target
NCT02649218 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 226 participants.
The verdict
NCT02649218, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 226 participants
- Enrollment target
Study Summary
A safety extension study to evaluate the long-term safety of QGE031 240 mg s.c. given every 4 weeks for 52 weeks in Chronic Spontaneous Urticaria (CSU) patients who completed study CQGE031C2201
Interventions
- BIOLOGICAL Ligelizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2016-05-24 |
| Est. Completion | 2019-05-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02649218
The ClinicalTrials.gov registry entry for NCT02649218 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 226 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ligelizumab is the first listed.
NCT02649218 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02649218 about?
NCT02649218 is a clinical study titled "A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients". A safety extension study to evaluate the long-term safety of QGE031 240 mg s.c. given every 4 weeks for 52 weeks in Chronic Spontaneous Urticaria (CSU) patients who completed study CQGE031C2201
What is the current status of trial NCT02649218?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 226 participants. The study started on 2016-05-24. Estimated completion is 2019-05-02.
What interventions are being tested in trial NCT02649218?
The interventions under investigation include: Ligelizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02649218?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.